JP2008507368A - 肺疾患を診断、モニタリングおよび治療するための方法 - Google Patents

肺疾患を診断、モニタリングおよび治療するための方法 Download PDF

Info

Publication number
JP2008507368A
JP2008507368A JP2007522850A JP2007522850A JP2008507368A JP 2008507368 A JP2008507368 A JP 2008507368A JP 2007522850 A JP2007522850 A JP 2007522850A JP 2007522850 A JP2007522850 A JP 2007522850A JP 2008507368 A JP2008507368 A JP 2008507368A
Authority
JP
Japan
Prior art keywords
group
subject
change
atp
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007522850A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008507368A5 (enExample
Inventor
ペレグ，アミール
バーンズ，ピーター，ジェイ．
ハリトノーヴ，セルゲイ，エー．
Original Assignee
デュスカ サイエンティフィック カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デュスカ サイエンティフィック カンパニー filed Critical デュスカ サイエンティフィック カンパニー
Publication of JP2008507368A publication Critical patent/JP2008507368A/ja
Publication of JP2008507368A5 publication Critical patent/JP2008507368A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2007522850A 2004-07-22 2005-07-22 肺疾患を診断、モニタリングおよび治療するための方法 Pending JP2008507368A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59010104P 2004-07-22 2004-07-22
US66203305P 2005-03-15 2005-03-15
PCT/US2005/026884 WO2006012639A2 (en) 2004-07-22 2005-07-22 Method of diagnosing, monitoring and treating pulmonary diseases

Publications (2)

Publication Number Publication Date
JP2008507368A true JP2008507368A (ja) 2008-03-13
JP2008507368A5 JP2008507368A5 (enExample) 2008-08-14

Family

ID=35786780

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007522850A Pending JP2008507368A (ja) 2004-07-22 2005-07-22 肺疾患を診断、モニタリングおよび治療するための方法

Country Status (6)

Country Link
US (2) US20060029548A1 (enExample)
EP (1) EP1773405A4 (enExample)
JP (1) JP2008507368A (enExample)
AU (1) AU2005266887B2 (enExample)
CA (1) CA2573565A1 (enExample)
WO (1) WO2006012639A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013022080A1 (ja) * 2011-08-10 2013-02-14 国立大学法人 富山大学 動物を用いた痺れ又は自発痛の評価方法
JP2016528301A (ja) * 2013-08-23 2016-09-15 アファレント ファーマシューティカルズ インコーポレイテッド 急性、亜急性または慢性の咳を治療するためのジアミノピリミジンｐ２ｘ３およびｐ２ｘ２／３受容体モジュレーター

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2620034C (en) * 2005-09-01 2013-10-01 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
US9402633B2 (en) 2006-03-13 2016-08-02 Pneumrx, Inc. Torque alleviating intra-airway lung volume reduction compressive implant structures
US8157837B2 (en) 2006-03-13 2012-04-17 Pneumrx, Inc. Minimally invasive lung volume reduction device and method
US8888800B2 (en) 2006-03-13 2014-11-18 Pneumrx, Inc. Lung volume reduction devices, methods, and systems
US8632605B2 (en) 2008-09-12 2014-01-21 Pneumrx, Inc. Elongated lung volume reduction devices, methods, and systems
KR101422901B1 (ko) 2009-02-13 2014-07-23 시오노기 앤드 컴파니, 리미티드 신규 트라이아진 유도체 및 그것을 함유하는 의약 조성물
US20100222294A1 (en) * 2009-02-27 2010-09-02 Duska Scientific Co. Formulations of ATP and Analogs of ATP
EP2432422A4 (en) 2009-05-18 2018-01-17 PneumRx, Inc. Cross-sectional modification during deployment of an elongate lung volume reduction device
US20130164386A1 (en) * 2010-06-17 2013-06-27 The Johns Hopkins University Targeting the Alpha3 Subnit of Na+-K+-ATPase for the Treatment of Cough with Sulfenamides
EP2604595B1 (en) 2010-08-10 2016-03-16 Shionogi&Co., Ltd. Triazine derivative and pharmaceutical compound that contains same and exhibits analgesic activity
US9550763B2 (en) 2012-02-09 2017-01-24 Shionogi & Co., Ltd. Heterocyclic ring and carbocyclic derivative
TWI637949B (zh) 2013-06-14 2018-10-11 塩野義製藥股份有限公司 胺基三衍生物及含有其等之醫藥組合物
WO2015061790A2 (en) 2013-10-25 2015-04-30 Pneumrx, Inc. Genetically-associated chronic obstructive pulmonary disease treatment
US10390838B1 (en) 2014-08-20 2019-08-27 Pneumrx, Inc. Tuned strength chronic obstructive pulmonary disease treatment
US11622716B2 (en) 2017-02-13 2023-04-11 Health Care Originals, Inc. Wearable physiological monitoring systems and methods
US11272864B2 (en) 2015-09-14 2022-03-15 Health Care Originals, Inc. Respiratory disease monitoring wearable apparatus
HUE061764T2 (hu) 2015-09-29 2023-08-28 Afferent Pharmaceuticals Inc Diaminopirimidin-P2X3 és P2X2/3 receptor modulátorok felhasználásra köhögés kezelésében
US11241579B2 (en) * 2016-04-22 2022-02-08 The Regents Of The University Of California Monitoring and modulation of parasympathetic nervous system
US10955269B2 (en) 2016-05-20 2021-03-23 Health Care Originals, Inc. Wearable apparatus
US20210278418A1 (en) * 2018-03-15 2021-09-09 The Chidlren's Medical Center Corporation Method for treating asthma or allergic disease
PL3862000T3 (pl) 2018-10-05 2024-03-18 Shionogi & Co., Ltd Lek na przewlekły kaszel
MX2022002941A (es) 2019-09-19 2022-04-06 Shionogi & Co Cristal de derivado de 1,3,5-triazina o solvato del mismo y metodo para producir el mismo.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002518983A (ja) * 1995-12-26 2002-06-25 アレゲニー ユニバーシティー オブ ザ ヘルス サイエンシズ 迷走神経トーンの調整方法
WO2002094767A2 (en) * 2001-05-18 2002-11-28 Abbott Laboratories Trisubstituted-n-[(1s)-1,2,3,4-tetrahydro-1-naphthalenyl] benzamides which inhibit p2x3 and p2x2/3 containing receptors

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5122466A (en) * 1989-06-13 1992-06-16 North Carolina State University Ballistic transformation of conifers
JP3121827B2 (ja) * 1990-09-04 2001-01-09 メドコ・リサーチ・インコーポレイテッド アデノシンまたはそのリン酸化誘導体を活性成分とする気管支収縮性肺疾患の診断剤
GB9109063D0 (en) * 1991-04-26 1991-06-12 Ici Plc Modification of lignin synthesis in plants
US5527586A (en) * 1992-03-18 1996-06-18 Printron, Inc. Apparatus and method for depositing metal particles on a dielectric substrate
US5348616A (en) * 1993-05-03 1994-09-20 Motorola, Inc. Method for patterning a mold
FR2709666B1 (fr) * 1993-09-07 1995-10-13 Oreal Composition cosmétique ou dermatologique constituée d'une émulsion huile dans eau à base de globules huileux pourvus d'un enrobage cristal liquide lamellaire.
EP0760850A1 (en) * 1994-05-27 1997-03-12 Glaxo Group Limited P2x RECEPTORS (PURINOCEPTOR FAMILY)
US5597613A (en) * 1994-12-30 1997-01-28 Honeywell Inc. Scale-up process for replicating large area diffractive optical elements
US6309580B1 (en) * 1995-11-15 2001-10-30 Regents Of The University Of Minnesota Release surfaces, particularly for use in nanoimprint lithography
US6482742B1 (en) * 2000-07-18 2002-11-19 Stephen Y. Chou Fluid pressure imprint lithography
US6204434B1 (en) * 1996-09-11 2001-03-20 Genesis Research & Development Corporation Limited Materials and methods for the modification of plant lignin content
US6653528B1 (en) * 1996-09-11 2003-11-25 Genesis Research & Development Corporation Limited Pinus radiata nucleic acids encoding O-methyl transferase and methods for the modification of plant lignin content therewith
US6410718B1 (en) * 1996-09-11 2002-06-25 Genesis Research & Development Corporation Ltd. Materials and methods for the modification of plant lignin content
US5850020A (en) * 1996-09-11 1998-12-15 Genesis Research & Development Corporation, Ltd. Materials and method for the modification of plant lignin content
US5735985A (en) * 1996-11-15 1998-04-07 Eastman Kodak Company Method for micromolding ceramic structures
JP2001518118A (ja) * 1997-03-25 2001-10-09 アレゲニー ユニバーシティー オブ ザ ヘルス サイエンシズ ヒト肥満細胞活性化のモジュレーション
US6225143B1 (en) * 1998-06-03 2001-05-01 Lsi Logic Corporation Flip-chip integrated circuit routing to I/O devices
US6110401A (en) * 1998-08-24 2000-08-29 Physical Optics Corporation Method and apparatus for replicating light shaping surface structures on a rigid substrate
US6190929B1 (en) * 1999-07-23 2001-02-20 Micron Technology, Inc. Methods of forming semiconductor devices and methods of forming field emission displays
US6517995B1 (en) * 1999-09-14 2003-02-11 Massachusetts Institute Of Technology Fabrication of finely featured devices by liquid embossing
DE60127098T2 (de) * 2000-01-31 2007-11-29 Genaera Corp. Inhibitoren der mucin-synthese
US6387787B1 (en) * 2001-03-02 2002-05-14 Motorola, Inc. Lithographic template and method of formation and use
US6716754B2 (en) * 2002-03-12 2004-04-06 Micron Technology, Inc. Methods of forming patterns and molds for semiconductor constructions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002518983A (ja) * 1995-12-26 2002-06-25 アレゲニー ユニバーシティー オブ ザ ヘルス サイエンシズ 迷走神経トーンの調整方法
WO2002094767A2 (en) * 2001-05-18 2002-11-28 Abbott Laboratories Trisubstituted-n-[(1s)-1,2,3,4-tetrahydro-1-naphthalenyl] benzamides which inhibit p2x3 and p2x2/3 containing receptors

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013022080A1 (ja) * 2011-08-10 2013-02-14 国立大学法人 富山大学 動物を用いた痺れ又は自発痛の評価方法
JPWO2013022080A1 (ja) * 2011-08-10 2015-03-05 国立大学法人富山大学 動物を用いた痺れ又は自発痛の評価方法
JP2016528301A (ja) * 2013-08-23 2016-09-15 アファレント ファーマシューティカルズ インコーポレイテッド 急性、亜急性または慢性の咳を治療するためのジアミノピリミジンｐ２ｘ３およびｐ２ｘ２／３受容体モジュレーター
US10206922B2 (en) 2013-08-23 2019-02-19 Afferent Pharmaceuticals, Inc. Substituted pyrimidines for treatment of chronic cough, neuronal hypersensitivity underlying chronic cough, neuronal hypersensitivity underlying sub-acute cough and neuronal hypersensitivity underlying acute cough
JP2019112459A (ja) * 2013-08-23 2019-07-11 アファレント ファーマシューティカルズ インコーポレイテッド 急性、亜急性または慢性の咳を治療するためのジアミノピリミジンｐ２ｘ３およびｐ２ｘ２／３受容体モジュレーター
JP2023002662A (ja) * 2013-08-23 2023-01-10 アファレント ファーマシューティカルズ インコーポレイテッド 急性、亜急性または慢性の咳を治療するためのジアミノピリミジンｐ２ｘ３およびｐ２ｘ２／３受容体モジュレーター
JP7210348B2 (ja) 2013-08-23 2023-01-23 アファレント ファーマシューティカルズ インコーポレイテッド 急性、亜急性または慢性の咳を治療するためのジアミノピリミジンｐ２ｘ３およびｐ２ｘ２／３受容体モジュレーター
JP7423725B2 (ja) 2013-08-23 2024-01-29 アファレント ファーマシューティカルズ インコーポレイテッド 急性、亜急性または慢性の咳を治療するためのジアミノピリミジンｐ２ｘ３およびｐ２ｘ２／３受容体モジュレーター

Also Published As

Publication number Publication date
CA2573565A1 (en) 2006-02-02
EP1773405A2 (en) 2007-04-18
WO2006012639A9 (en) 2006-03-16
WO2006012639A2 (en) 2006-02-02
WO2006012639A3 (en) 2006-06-22
US20100286274A1 (en) 2010-11-11
US20060029548A1 (en) 2006-02-09
AU2005266887B2 (en) 2011-08-18
AU2005266887A1 (en) 2006-02-02
EP1773405A4 (en) 2011-10-05

Similar Documents

Publication Publication Date Title
US20100286274A1 (en) Methods of Diagnosing, Monitoring and Treating Pulmonary Diseases
Moskowitz et al. Neocortical spreading depression provokes the expression of c-fos protein-like immunoreactivity within trigeminal nucleus caudalis via trigeminovascular mechanisms
Qiu et al. Dexmedetomidine activation of dopamine neurons in the ventral tegmental area attenuates the depth of sedation in mice
Bonvini et al. Targeting TRP channels for chronic cough: from bench to bedside
Basoglu et al. Effects of aerosolized adenosine 5′-triphosphate in smokers and patients with COPD
Taylor et al. Airway reactivity in chronic obstructive pulmonary disease: failure of in vivo methacholine responsiveness to correlate with cholinergic, adrenergic, or nonadrenergic responses in vitro
Chou et al. Differential effects of airway afferent nerve subtypes on cough and respiration in anesthetized guinea pigs
Shao et al. Inhaled nicotine equivalent to cigarette smoking disrupts systemic and uterine hemodynamics and induces cardiac arrhythmia in pregnant rats
Canning et al. Sensory nerves and airway irritability
Landgraf et al. Vasopressin and oxytocin in rat brain in response to prostaglandin fever
Benson et al. Bronchial reactivity: interaction between vagal stimulation and inhaled histamine
Hsieh et al. Coughing in small animal patients
Patterson et al. The use of IgE mediated responses as a pharmacologic test system. The effect of disodium cromoglycate in respiratory and cutaneous reactions and on the electrocardiograms of rhesus monkeys
Borsody et al. Alteration of locus coeruleus neuronal activity by interleukin-1 and the involvement of endogenous corticotropin-releasing hormone
Cinelli et al. Suppression of the cough reflex by α2‐adrenergic receptor agonists in the rabbit
Dong et al. Sensitivity of rat temporalis muscle afferent fibers to peripheral N-methyl-D-aspartate receptor activation
Buron et al. Oxytocin modulates respiratory heart rate variability through a hypothalamus–brainstem–heart neuronal pathway
Leemans et al. Functional response to inhaled salbutamol and/or ipratropium bromide in Ascaris suum-sensitised cats with allergen-induced bronchospasms
Gazerani et al. Sensitization of rat facial cutaneous mechanoreceptors by activation of peripheral N-methyl-d-aspartate receptors
Nantwi et al. Adenosine A1 receptor mRNA expression and the effects of systemic theophylline administration on respiratory function 4 months after C2 hemisection
Crimi et al. Changes in neurokinin A (NKA) airway responsiveness with inhaled frusemide in asthma.
US20200215085A1 (en) Method to Abate Acute Airway Hypersensitivity and Asthma Attacks
Rice et al. Tachykinin‐induced bronchoconstriction in sheep is NK‐1 receptor mediated and exhibits tachyphylaxis
Buron et al. The oxytocin-modulated brain circuit that synchronizes heart rate with breathing
Lee Pulmonary Stress Induced by Hyperthermia: Role of Airway Sensory Nerves

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080624

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080624

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110712

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111007

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111017

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111101

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120522

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121106